{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:22:16Z","timestamp":1792848136836,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:p>Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile gliomas, leading to high rates of recurrence and poor response to current treatments. The blood-brain barrier and the heterogeneity of gliomas complicate the development of a single treatment strategy for all cases. This review aims to evaluate the efficacy and safety of combination therapies, particularly Dabrafenib and Trametinib, in pediatric gliomas with BRAF V600 mutations and discusses their potential in improving clinical outcomes. A review of recent clinical trials was conducted to assess the impact of targeted therapies, especially the combination of Dabrafenib and Trametinib, on glioma treatment outcomes. Additional therapies are also explored. Combination therapy with Dabrafenib, a BRAF kinase inhibitor, and Trametinib, a MEK inhibitor, has shown significant improvement in overall survival and progression-free survival for pediatric patients with BRAF V600-mutant gliomas. Recent clinical data from 2023 demonstrated enhanced tumor control, reduced relapse rates, and improved safety profiles compared to conventional therapies. Dabrafenib and Trametinib offer a promising targeted therapy for juvenile gliomas with BRAF V600 mutations, with better survival outcomes and manageable safety profiles. However, challenges remain in managing side effects such as fever, headache, lethargy, and rash. Further research into resistance mechanisms and long-term effects is necessary to optimize treatment strategies. Other therapies, such as everolimus and Selumetinib, also show potential and warrant further investigation.<\/jats:p>","DOI":"10.1097\/md.0000000000040735","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:00:47Z","timestamp":1733778047000},"page":"e40735","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8472-5721","authenticated-orcid":false,"given":"Maryam Abdul","family":"Wahid","sequence":"first","affiliation":[{"name":"Dow Medical College Karachi, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7616-9143","authenticated-orcid":false,"given":"Muhammad Taimur","family":"Khan","sequence":"additional","affiliation":[{"name":"Abbottabad International Medical College, Abbottabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7995-9933","authenticated-orcid":false,"given":"Jawairya Muhammad","family":"Hussain","sequence":"additional","affiliation":[{"name":"Karachi Medical and Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0647-8181","authenticated-orcid":false,"given":"Hurais","family":"Malik","sequence":"additional","affiliation":[{"name":"Fazaia Ruth Pfau Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9397-1926","authenticated-orcid":false,"given":"Shahood Ahmed","family":"Umar","sequence":"additional","affiliation":[{"name":"Ziauddin Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanila","family":"Mughal","sequence":"additional","affiliation":[{"name":"Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-7840","authenticated-orcid":false,"given":"Muhammad","family":"Hasanain","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital, Internal Medicine, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2429-515X","authenticated-orcid":false,"given":"Muhammad Umair","family":"Anjum","sequence":"additional","affiliation":[{"name":"Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-9368","authenticated-orcid":false,"given":"Mohammed","family":"Mahmmoud Fadelallah Eljack","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Bakht Alruda, Ad Duwaym, Sudan"},{"name":"Kassala Teaching Hospital, Kassala, Sudan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 4","key":"R1-20250504","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-Oncology"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of Dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a Phase I\/IIa study.","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics.","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11910-023-01257-3","article-title":"Treatment of pediatric low-grade gliomas.","volume":"23","author":"Sait","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e15495","DOI":"10.1016\/j.heliyon.2023.e15495","article-title":"A new approach to the development and assessment of doxorubicin-loaded nanoliposomes for the treatment of osteosarcoma in 2D and 3D cell culture systems.","volume":"9","author":"Parchami","year":"2023","journal-title":"Heliyon"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.3390\/ma14133706","article-title":"Nanomaterials for the diagnosis and treatment of head and neck cancers: a review.","volume":"14","author":"Ruiz-Pulido","year":"2021","journal-title":"Materials (Basel)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/cco-22-120","article-title":"2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.","volume":"12","author":"Thomas","year":"2023","journal-title":"Chin Clin Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/cancers15041268","article-title":"Molecular heterogeneity in BRAF-mutant gliomas: diagnostic, prognostic, and therapeutic implications.","volume":"15","author":"Lhermitte","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"621831","DOI":"10.3389\/fnmol.2021.621831","article-title":"Current approaches for glioma gene therapy and virotherapy.","volume":"14","author":"Banerjee","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management.","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"733323","DOI":"10.3389\/fneur.2021.733323","article-title":"Advanced magnetic resonance imaging in pediatric glioblastomas.","volume":"12","author":"Gon\u00e7alves","year":"2021","journal-title":"Front Neurol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes.","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3174\/ajnr.A6998","article-title":"Radiomics of pediatric low-grade gliomas: toward a pretherapeutic differentiation of BRAF-mutated and BRAF-fused tumors.","volume":"42","author":"Wagner","year":"2021","journal-title":"AJNR Am J Neuroradiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/neuonc\/noab247","article-title":"Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.","volume":"24","author":"Andrews","year":"2022","journal-title":"Neuro Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with Dabrafenib in pediatric BRAF V600-mutant low-grade glioma.","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-023-00359-y","article-title":"Integrated molecular and clinical analysis of BRAF-mutant glioma in adults.","volume":"7","author":"Schreck","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"R19-20250504","article-title":"FDA Grants Accelerated Approval to Dabrafenib."},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1200\/JCO.23.00558","article-title":"Investigators involved in the high-grade glioma cohort. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed\/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.","volume":"41","author":"Hargrave","year":"2023","journal-title":"J Clin Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in pediatric glioma with BRAF V600 mutations.","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of Trametinib monotherapy or in combination with Dabrafenib in pediatric BRAF V600\u2013mutant low-grade glioma.","volume":"41","author":"Bouffet","year":"2022","journal-title":"J Clin Oncol"},{"key":"R23-20250504"},{"key":"R24-20250504"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/jgo.2017.01.04","article-title":"Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.","volume":"8","author":"Au","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/neuonc\/noz022","article-title":"Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.","volume":"21","author":"Miklja","year":"2019","journal-title":"Neuro Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H.","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e389322","DOI":"10.1200\/EDBK_389322","article-title":"Molecular profiling in neuro-oncology: where we are, where we\u2019re heading, and how we ensure everyone can come along.","volume":"43","author":"Porter","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1067252","DOI":"10.3389\/fonc.2022.1067252","article-title":"Implications of BRAF V600E mutation in gliomas: molecular considerations, prognostic value and treatment evolution.","volume":"12","author":"Di Nunno","year":"2023","journal-title":"Front Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000534731","article-title":"Successful treatment with Dabrafenib\/Trametinib of a malignantly transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: a case report and review of the literature.","volume":"17","author":"Vermeulen","year":"2024","journal-title":"Case Rep Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers.","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer.","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","article-title":"Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"e28787","DOI":"10.1002\/pbc.28787","article-title":"A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.","volume":"68","author":"Wright","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.21.02840","article-title":"Phase II study of Selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: Arm E of the NCI-COG pediatric MATCH trial.","volume":"40","author":"Eckstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","article-title":"Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi): a multicenter, phase I\/II study.","volume":"17","author":"Trippett","year":"2022","journal-title":"Target Oncol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3390\/cancers14174264","article-title":"BRAF and MEK targeted therapies in pediatric central nervous system tumors.","volume":"14","author":"Talloa","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"390","DOI":"10.21873\/cgp.20328","article-title":"Molecular genetics and targeted therapies for paediatric high-grade glioma.","volume":"19","author":"Rallis","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1002\/ONCO.13519","article-title":"Targetable BRAF and RAF1 alterations in advanced pediatric cancers.","volume":"26","author":"Rankin","year":"2021","journal-title":"Oncologist"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11060-023-04241-6","article-title":"How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.","volume":"161","author":"Perwein","year":"2023","journal-title":"J Neurooncol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ijc.34602","article-title":"Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.","volume":"153","author":"Fragale","year":"2023","journal-title":"Int J Cancer"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:07:39Z","timestamp":1746320859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":41,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040735","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}